Cue Biopharma, Inc.
For the period ended Jun 30, 2026. Filed Aug 14, 2026.
View on SEC.govAbout this filing
A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.
Jun 30, 2026 · Filed Aug 14, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Item 6. Exhibits
| Incorporated by Reference | ||||||
|---|---|---|---|---|---|---|
| ExhibitNumber | Exhibit Description | FiledHerewith | Form | Exhibit | Filing Date | Registration/File No. |
| 3.1 | Certificate of Amendment to the Company’s Amended and Restated Certificate of Incorporation, as amended | 8-K | 3.1 | 4/22/2026 | 001-38327 | |
| 4.1 | Form of Pre-Funded Warrant to Purchase Common Stock to be issued to Ascendant Health Sciences Ltd. | 8-K | 4.1 | 5/1/2026 | 001-38327 | |
| 4.2 | Form of Pre-Funded Warrant to Purchase Common Stock to be issued to the Investors | 8-K | 4.2 | 5/1/2026 | 001-38327 | |
| 4.3 | Form of Warrant to Purchase Common Stock to be issued to the Investors | 8-K | 4.3 | 5/1/2026 | 001-38327 | |
| 10.1 | Form of Investor Agreement by and among the Company and Ascendant Health Sciences Ltd. | 8-K | 10.2 | 5/1/2026 | 001-38327 | |
| 10.2 | Form of Registration Rights Agreement, dated April 30, 2026, by and among the Company and the Investors | 8-K | 10.4 | 5/1/2026 | 001-38327 | |
| 10.3 | 2026 Inducement Stock Incentive Plan | 8-K | 10.5 | 5/1/2026 | 001-38327 | |
| 10.4# | License Agreement, dated as of April 30, 2026, by and between the Company and Ascendant Health Sciences Ltd. | X | ||||
| 10.5* | Executive Employment Agreement, dated as of April 29, 2026, by and between the Company and Shao-Lee-Lin | X | ||||
| 10.6* | Separation and Release of Claims Agreement, dated as of April 30, 2026, by and between the Company and Lucinda Warren | X | ||||
| 10.7# | Amendment to License Agreement with Ascendant Health Ltd. | X | ||||
| 31.1 | Certification Pursuant to Rule 13a-14(a) or Rule 15d-14(a) of the Securities Exchange Act of 1934 | X | ||||
| 31.2 | Certification Pursuant to Rule 13a-14(a) or Rule 15d-14(a) of the Securities Exchange Act of 1934 | X | ||||
| 32.1 | Certification Pursuant to 18 U.S.C. Section 1350, as Adopted Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002 | X | ||||
| 32.2 | Certification Pursuant to 18 U.S.C. Section 1350, as Adopted Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002 | X | ||||
| 101.INS | Inline XBRL Instance Document – the instance document does not appear in the Interactive Data File because its XBRL tags are embedded within the Inline XBRL document. | X | ||||
| 101.SCH | Inline XBRL Taxonomy Extension Schema With Embedded Linkbase Documents | X | ||||
| 104 | The cover page from the Company’s Quarterly Report on Form 10-Q for the quarter ended June 30, 2026, has been formatted in Inline XBRL. | X | ||||
*Indicates management compensatory plan, contract or arrangement.
Portions of this exhibit have been omitted pursuant to Item 601(b)(10)(iv) of Regulation S-K.
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.
| Cue Biopharma, Inc. | ||
| Dated: August 14, 2026 | By: | /s/ Shao-Lee Lin |
|---|---|---|
| Shao-Lee LinPresident and Chief Executive Officer (Principal Executive Officer) | ||
| Cue Biopharma, Inc. | ||
| Dated: August 14, 2026 | By: | /s/ James Ahlers |
|---|---|---|
| James AhlersChief Financial Officer(Principal Financial Officer) | ||
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.